Résumé
The quantification of cerebrospinal fluid (CSF) biomarkers (Amyloid beta peptides [Aß1-40 and Aß1-42], tau protein and its phosphorylated form phospho-tau (ptau(181)) is progressively implemented in specialized laboratories as an aid for the multidisciplinary diagnosis of Alzheimer’s disease (AD). However, no consensus has yet been reached between the different laboratories involved to define the most appropriate conclusions/comments based on the profile of the quantified biomarkers. Therefore, although the methods of biomarker analysis are often similar between the laboratories involved in this clinical task, the conclusions reported to the responsible physician (neurologist or psychiatrist) may be very different. Harmonization of this report is therefore necessary so that the management and stratification of patients in research protocols can be similar regardless of where the analysis is performed. The objective of the present work, supported by the ISTAART Biofluid Based Biomarkers PIA, is to propose a harmonized report between the different specialized laboratories involved in accordance with their own practice, and to whom the report is transmitted.